X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the merger, the company focused on the development of NGM707, a novel dual antagonist antibody inhibiting ILT2 and ILT4. It is currently enrolling patients for the treatment of Mesothelioma, Glioblastoma and Renal Cell Carcinoma.
Lead Product(s): NGM707,Pembrolizumab
Therapeutic Area: Oncology Product Name: NGM707
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: The Column Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 26, 2024
Details:
NGM707 is a dual ILT2/ILT4 antagonist antibody, which is under phase 1 clinical development in combination with Keytruda (pembrolizumab) for the treatment of mesothelioma, glioblastoma & renal cell carcinoma.
Lead Product(s): NGM707,Pembrolizumab
Therapeutic Area: Oncology Product Name: NGM707
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
NGM707, ILT2/ILT4 antagonist antibody, is the most advanced of three early clinical-stage product candidates in NGM Bio’s myeloid checkpoint and reprogramming portfolio.
Lead Product(s): NGM707,Pembrolizumab
Therapeutic Area: Oncology Product Name: NGM707
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
NGM936, a ILT3 x CD3 bispecific T cell engager product candidate engineered to direct T cell-mediated killing of ILT3-positive cancer cells for the treatment of patients with multiple myeloma.
Lead Product(s): NGM936
Therapeutic Area: Oncology Product Name: NGM936
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2022
Details:
NGM621 demonstrated a favorable safety profile, with no evidence of increased choroidal neovascularization (CNV) conversions and numerically fewer cases of CNV in NGM621-treated patients compared to sham. In addition, there were no drug-related serious adverse events.
Lead Product(s): NGM621
Therapeutic Area: Ophthalmology Product Name: NGM621
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
NGM621 is a humanized IgG1 monoclonal antibody engineered to potently inhibit activity of complement C3 with the treatment goal of reducing disease progression in patients with geographic atrophy, and with the potential for every eight week dosing without pegylation.
Lead Product(s): NGM621
Therapeutic Area: Ophthalmology Product Name: NGM621
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2022
Details:
These results demonstrate that treatment with NGM120 was well tolerated to date in the study with no dose-limiting toxicities and provided encouraging signals of anti-cancer activity in patients with metastatic pancreatic cancer.
Lead Product(s): NGM120,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Product Name: NGM120
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
NGM120 is an antagonist antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15) signaling.
Lead Product(s): NGM120
Therapeutic Area: Oncology Product Name: NGM120
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
Details:
NGM120 is an antagonist antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15) signaling.
Lead Product(s): NGM120
Therapeutic Area: Oncology Product Name: NGM120
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
NGM438 is an antagonist antibody product candidate engineered to inhibit LAIR1 being developed by NGM Bio for the treatment of patients with advanced solid tumors.
Lead Product(s): NGM438,Pembrolizumab
Therapeutic Area: Oncology Product Name: NGM438
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
